Last reviewed · How we verify
OFF in experimental arm
At a glance
| Generic name | OFF in experimental arm |
|---|---|
| Also known as | Eloxatin, Calciumfolinat, 5-Fluorouracil |
| Sponsor | CONKO-Studiengruppe |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effects of Dual Task-Oriented Circuit Training on Walking Recovery in Sub-acute Stroke (NA)
- KD Treatment for Super-refractory Status Epilepticus (NA)
- Dexmedotomidine for Acute Pain Control in Patients With Multiple Rib FracturesRandomized Controlled Trial (PHASE4)
- Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer (PHASE2)
- Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia (PHASE3)
- Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF) (NA)
- Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma (PHASE2)
- Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OFF in experimental arm CI brief — competitive landscape report
- OFF in experimental arm updates RSS · CI watch RSS
- CONKO-Studiengruppe portfolio CI